Skip to content
Company Analysis

Alvotech Warrant ALVOW

A comprehensive view of key metrics, scores, and financial health for Alvotech Warrant

Overview of Alvotech

ALVOW NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech
Alvotech (ALVOW), in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.30, about 0.0% overvalued vs fair value, ranked 924/1145 in sector.
Metrics Rev Growth 19.7% ROE -8.0% Gross Margin 59.8%
USD 0.30
58.23%
(Delayed)
• Vol 90d: 356.8%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 82%
Confidence: 83%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.alvotech.com
HQ Luxembourg
Employees 1,012
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$586.3M
19.7%%
Gross Profit
$350.8M
15.2%%
R&D Expense
$184.2M
7.5%%
Operating Income (EBIT)
$273.2M
529.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
-18.4%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
4
Active Leaks
1/4
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Alvotech Warrant's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Cost Leadership Position Operating margin at 78.8th percentile with strong OpEx control demonstrates cost leadership.
  • ROIC Sustainably Above Peers ROIC at 70.7th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.18), suggesting weak customer stickiness.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.31), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing ALVOW's balance between Growth (43.7%), Profitability (31.4%), and Safety (24.9%). Growth 44% Safety 25% Profitability 31%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

88th percentile vs peers
88
Key Signals
Rev Growth YoY 19.7% 81p Revenue CAGR 3Y 91.8% 95p
Strengths
  • Growth performance in top 20% of peers (percentile: 88)
  • Rev Growth YoY in top 20% of peers (19.7%, 81th percentile)
  • Revenue CAGR 3Y in top 20% of peers (91.8%, 95th percentile)
  • EBIT Margin in top 20% of peers (46.6%, 97th percentile)
Risks

No significant risks identified for this axis.

Profitability

63th percentile vs peers
63
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

50th percentile vs peers
50
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Alvotech Warrant.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000